Sorafenib is an orally bioavailable multi-kinase inhibitor that was approved by the Food and Drug Administration (FDA) for clinical use in the treatment of HCC in 2007 and can block tumor angiogenesis by inhibiting VEGFR and platelet-derived growth factor receptor (PDGFR) (32). The gene discussed is KDR; the disease is hepatocellular carcinoma.